Information Provided By:
Fly News Breaks for February 25, 2020
TBPH
Feb 25, 2020 | 11:44 EDT
H.C. Wainwright analyst Douglas Tsao raised the firm's price target on Theravance Biopharma to $32 from $30 after a quarter in which Yupelri "impressed." The analyst, who thinks this year should be pivotal for the company given it has several key readouts, including for some drugs with "blockbuster potential," keeps a Buy rating on Theravance shares.
News For TBPH From the Last 2 Days
There are no results for your query TBPH